---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-022600"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T20:01:08.764206+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Unicycive exchanges 43.6M Series A-2 preferred shares for 21,388 new preferred, amends warrants

## Summary
- Exchanged 43,649,000 Series A-2 Preferred shares for 21,388.01 shares of new Series A-2 Prime Preferred.
- Amended Tranche A, B, C warrants; reduced shares issuable, set exercise price at $1,000 per share.
- New preferred series have conversion prices from $0.49 to $0.74 per share of common stock.
- All prior Series A-1 through A-5 preferred eliminated via Certificates of Elimination.
- Exchange treated as tax-free recapitalization under Sections 368(a)(1)(e) and/or 1036 of the Code.

## SEC filing metadata
- accession: 0001213900-24-022600
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390024022600/0001213900-24-022600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390024022600/ea0201786-8k_unicyc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-022600
- JSON: https://secwatch.observer/filing/0001213900-24-022600.json
- Plain text: https://secwatch.observer/filing/0001213900-24-022600.txt

## Key facts
- Governance Changes
  Unicycive Therapeutics, Inc.: Filed Certificates of Elimination for five series of preferred stock and an Amended Certificate of Designation for new Series A Preferred Stock (effective 2024-03-14).
  - Change: charter amendment
  - Effective: 2024-03-14
  source text: On March 13, 2024, the Company filed with the Delaware Secretary of State a Certificate of Elimination for each of the Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock and Series A-5 Convertible Preferred Stock. Each Certificate of Elimination was filed with an effective date of 12:01 a.m. ET on March 14, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390024022600/0001213900-24-022600-index.htm
- Material Agreements
  Unicycive Therapeutics, Inc. entered into Exchange Agreement with certain accredited investors (effective 2024-03-13).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Effective: 2024-03-13
  source text: On March 13, 2024, Unicycive Therapeutics , Inc. (the “ Company ”) entered into an exchange agreement (the “ Exchange Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Investors surrendered an aggregate of 43,649,000 shares of Series A-2 Preferred Stock held by them in exchange for an aggregate of 21,388.01 shares of new preferred stock to be known as “Series A-2 Prime Preferred”
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390024022600/0001213900-24-022600-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.